Skip to main contentPsst! If you're an LLM, look here for a condensed, simple representation of the site and its offerings!

LiveFree Webinar — Wednesday, September 2 at 2:00 PM EDT

Register Free →

Technical R&D Execution in Specialized Domains

Active
SBIR / STTR

Contract Overview

Solicitation details, issuing organization, response deadlines, documents, and interested companies for this government contract opportunity.

General Info

Agency

U.S. Department of Defense → U.S. Air ForceView Agency

NAICS

541711 - Research and Development in BiotechnologyView NAICS

Place of Performance

Not specified

Set-Aside

SBA

Documents

This scope was carved out of DAF26BX05-DV509.

The full solicitation package (1 document), including the RFP, is on the prime solicitation, not on this scope.

View the prime solicitation

Power the space: high-voltage radiation hardened power switches for space power and propulsion

AI Contract Breakdown

Uniform Contract Format

No contract breakdown available.

Cannot generate Contract Breakdown because no documents were found from this contract's source.

Timeline

Posted

subcontract

Response Deadline

Submission deadline

Response Deadline

Ready to pursue this opportunity?

Start your free trial to track this contract, build proposals with AI assistance, and manage your pipeline.

Organization & Contact Information

Show more
AgencyU.S. Department of Defense → U.S. Air Force
ContactsNo contacts available
OfficeN/A
Organization / Agency
U.S. Department of Defense → U.S. Air Force
View Agency Profile
Office AddressN/A
ContactsNo contact information available

Full Description

Show more
Perform applied R&D in technical fields such as AI/ML, biotechnology, materials science, or unmanned systems under Phase I SBIR awards.

Similar Contracts

Same NAICS industry code

NAICS: 541711
Federal
Integrated Phase I/II Clinical Trial DesignThe contract seeks the design and protocol development for an integrated Phase I/II clinical trial to evaluate ibogaine as a potential treatment for opioid use disorder, focusing on safety, optimal dosing, and therapeutic efficacy. The effort requires a comprehensive clinical framework that seamlessly merges the objectives of Phase I, which prioritizes dose escalation and toxicity profiling, with those of Phase II, which assesses preliminary effectiveness in reducing opioid dependence and withdrawal symptoms. The protocol must adhere to rigorous scientific and regulatory standards, incorporating appropriate patient selection criteria, monitoring procedures, endpoints, and risk mitigation strategies for a substance with significant pharmacological and safety considerations. The work is being pursued as a subcontract under the Advanced Research Projects Agency for Health, part of the Department of Health and Human Services, with a NAICS code indicating research and development in the life sciences. The solicitation was posted on August 5, 2026, and responses are due by October 15, 2026. The project is situated within a broader initiative to advance novel therapeutic interventions for the opioid crisis, requiring innovative trial design that balances exploratory research with clinical feasibility. There is no specified set-aside designation or location restriction for performance, indicating flexibility in execution while emphasizing scientific merit and regulatory alignment as key evaluation criteria.
Advanced Research Projects Agency For Health (arpa-H)

POSTED

22 days ago

DEADLINE

in about 2 months
View Details
NAICS: 541711
Federal
Clinical Trial Design and Efficacy Data GenerationThe contract calls for the design and execution of clinical trials aimed at evaluating the safety, wound closure, infection control, and functional regeneration outcomes of medical interventions in patients with burn and trauma injuries. The work requires rigorous scientific methodology to generate robust efficacy data that supports regulatory and clinical adoption, with a focus on measurable endpoints related to tissue recovery and patient outcomes. The trials must be conducted in accordance with established clinical standards and are intended to provide evidence of therapeutic effectiveness under real-world conditions. This is a subcontract under the Aspr Administration for Strategic Preparedness and Response, part of the Department of Health and Human Services, with a solicitation posted on July 28, 2026, and a response deadline of August 28, 2026. The work is classified under NAICS code 541711, indicating research and development in the life sciences. The performance location is designated with a zip code of 77416, though no specific city or state is provided, and no point of contact details are listed. The contract does not include a set-aside designation, and all eligible entities may respond, with emphasis placed on technical capability, trial design expertise, and experience in trauma and burn clinical research.
Aspr Administration For Strategic Preparedness And Response

POSTED

about 1 month ago

DEADLINE

in 1 day
View Details
NAICS: 541711
Grant
Preclinical Animal Studies for Neurofibromatosis ResearchThe contract seeks to conduct preclinical in vivo studies using genetically engineered mouse models or alternative animal models of neurofibromatosis to assess the efficacy of therapeutic interventions, track tumor progression, and investigate underlying biological mechanisms. The work requires advanced expertise in animal modeling, tumor biology, and preclinical drug evaluation, with a focus on generating robust, reproducible data to support future clinical translation. All studies must be conducted in accordance with established ethical and scientific standards for animal research, with detailed documentation of methodologies, outcomes, and adverse events. This subcontract is issued under the Defense Health Agency Contracting Activity and falls under NAICS code 541711, indicating it supports research and development in the physical, engineering, and life sciences. The solicitation was posted on June 25, 2026, with a response deadline of September 22, 2026, and is open to qualified entities capable of executing complex preclinical studies. While the place of performance and point of contact details are unspecified, successful proposers must demonstrate capacity to manage animal facilities, comply with regulatory requirements, and deliver high-quality, timely results in support of neurofibromatosis research objectives under the Department of Defense.
Defense Health Agency Contracting Activity - Dhaca

POSTED

2 months ago

DEADLINE

in 26 days
View Details

More opportunities from U.S. Department of Defense → U.S. Air Force

Same awarding agency